Comparison of the Results of Bronchoalveolar Lavage Culture and Endotracheal Aspirate Culture in Intubated Critically Ill COVID-19 Patients
NCT05403489 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67
Last updated 2022-06-03
Summary
Introduction: Secondary pneumonia is frequently seen in COVID-19 cases followed up intubated, and high mortality rates can be observed. Isolation of the agent with bronchoalveolar lavage (BAL) culture or endotracheal aspirate (ETA) culture may increase the success of treatment. This study aimed to retrospectively analyze the results of BAL and ETA cultures in intubated COVID-19 cases.
Methods: We routinely apply BAL culture with bronchoscopy or ETA culture within the first 48 hours after intubating. We retrospectively screened cases who underwent BAL and ETA. They were divided into two groups: Group B and E. Evaluated parameters were compared in both groups.
Results: Demographic data and blood test results were similar in both groups. Intensive care unit (ICU) and intubation durations, and culture positivity were statistically significantly higher in Group B. Although not statistically significant, the mortality rate was higher in Group E. The most growth microorganisms were Candida species.
Conclusion: Mortality rates were consistent with the literature. Since the microorganism isolation rate is higher with BAL and antimicrobial treatment is applied more effectively; early deaths were prevented and stay periods were prolonged. In contrast, these durations were shorter in the ETA group due to higher mortality. In intubated COVID-19 cases, a more effective treatment process can be carried out by clearing the airway with fiberoptic bronchoscopy and by specifically planning the treatment according to the BAL culture. This may have a positive effect on prognosis and mortality.
Conditions
- Bronchoalveolar Lavage
- COVID-19 Pneumonia
- Critical Illness
Interventions
- PROCEDURE
-
Bronchoalveolar lavage
In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
- PROCEDURE
-
endotracheal aspirate culture
In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
Sponsors & Collaborators
-
Basri Cakiroglu
lead OTHER
Principal Investigators
-
Hasan Huseyin Kilic · Hisar Intercontinental Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-01
- Primary Completion
- 2021-12-31
- Completion
- 2022-05-31
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Sepsis in Respiratory Intensive Care Unit
NCT05240157 ·Status: COMPLETED
-
Bronchoalveolar Lavages for Cytologic Assessment in Intensive Care Unit Patients
NCT03098888 ·Status: COMPLETED
-
Pilot Study on Cytokine Filtration in COVID-19 ARDS
NCT04361526 ·Status: UNKNOWN ·Phase: NA
-
Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
NCT06134674 ·Status: COMPLETED
-
Effectiveness of the Cytokine Hemadsorption on Sepsis
NCT05057455 ·Status: COMPLETED
-
EFFECTS OF EXTRACORPOREAL CYTOKINE ELIMINATION ON HEMODYNAMIA AND MORTALITY IN CRITICAL PATIENTS
NCT05984407 ·Status: UNKNOWN
-
Effect of FAST HUGS WITH ICU Approach on Length of Intensive Care Unit Stay in Patients With Hypoxic Respiratory Failure
NCT06901050 ·Status: RECRUITING ·Phase: NA
-
Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.
NCT05624684 ·Status: COMPLETED
-
High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
NCT05133635 ·Status: WITHDRAWN ·Phase: PHASE4
-
Characterization Immunology, Biochemical and Lung Microbiome, Correlated With the Ventilation Associated Pneumonia (VAP)
NCT04944823 ·Status: UNKNOWN
-
Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care
NCT05474157 ·Status: TERMINATED
-
Interleukine 6 as a Predictor of Outcome in Mechanically Ventilated Patients With Covid 19
NCT05274503 ·Status: COMPLETED
-
Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS
NCT05933291 ·Status: COMPLETED
-
Scoring Systems covid19
NCT05308524 ·Status: UNKNOWN
-
Lung Microbiota Analysis in Critically Ill Patients Admitted to the Intensive Care Unit.
NCT04271345 ·Status: UNKNOWN
-
Recovery of Patients From COVID-19 After Critical Illness
NCT04401254 ·Status: COMPLETED
-
Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19
NCT04586114 ·Status: UNKNOWN
-
Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study
NCT04893031 ·Status: COMPLETED
-
Effect of Sinovac on Survival in Intensive Care Unit
NCT04956562 ·Status: COMPLETED
-
The Prognostic Role of Red Blood Cell Distribution (RDW) in Severe COVID-19 Patients
NCT07244731 ·Status: COMPLETED
-
ICU Mortality Predictors of Trauma Patients
NCT03894111 ·Status: COMPLETED
-
Use of Reticulocyte Ratio and Neutrophil / Lymphocyte Ratio in the Diagnosis of Ventilator-associated Pneumonia
NCT04620941 ·Status: COMPLETED
-
Effectiveness of Convalescent Immune Plasma Therapy
NCT04442958 ·Status: COMPLETED ·Phase: NA
-
Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study
NCT07289711 ·Status: RECRUITING
-
Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
NCT03641690 ·Status: COMPLETED